<div id="readability-page-1"><p>Altman Advisors Inc. acquired a new position in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 9,711 shares of the company's stock, valued at approximately $1,574,000.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>ORIC: Working with Two Pharma Giants, Analysts See +100% Upside</li></ul><p>Other large investors have also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in  Johnson &amp; Johnson during the 2nd quarter worth $27,000.  Highline Wealth Partners LLC bought a new position in  Johnson &amp; Johnson during the 3rd quarter worth $31,000.  Mowery &amp; Schoenfeld Wealth Management LLC increased its position in  Johnson &amp; Johnson by 58.7% during the 3rd quarter. Mowery &amp; Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares during the period.  Morton Brown Family Wealth LLC increased its position in shares of  Johnson &amp; Johnson by 400.0% in the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company's stock worth $41,000 after purchasing an additional 200 shares during the period.  Finally, MFA Wealth Advisors LLC bought a new position in shares of  Johnson &amp; Johnson in the second quarter worth $43,000. Institutional investors own  69.55% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>A number of research analysts recently commented on the company. Guggenheim raised their price target on Johnson &amp; Johnson from $156.00 to $162.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, November 6th. Wells Fargo &amp; Company raised their price target on Johnson &amp; Johnson from $163.00 to $166.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, October 16th. StockNews.com upgraded Johnson &amp; Johnson from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, September 14th. Daiwa America cut Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada raised their price target on Johnson &amp; Johnson from $178.00 to $181.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one  has issued  a strong buy rating to the company. According to MarketBeat, Johnson &amp; Johnson presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $175.94.</p><ul><li>Discover the 3 Best-Performing Biotech IPO Stocks of 2024</li></ul><p><b>Read Our Latest Stock Analysis on JNJ</b></p><h2>Johnson &amp; Johnson Stock Performance</h2><p>Shares of JNJ stock opened at $152.30 on Wednesday. The business's 50-day moving average price is $160.83 and its 200-day moving average price is $156.19. Johnson &amp; Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The firm has a market capitalization of $366.68 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 2.74 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. </p><ul><li>Best Pharma Stocks for Long-Term Investors: Growth and Dividends</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. Johnson &amp; Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the firm posted $2.66 earnings per share. The business's revenue for the quarter was up 5.2% on a year-over-year basis.  Equities research analysts forecast that  Johnson &amp; Johnson will post 9.93 EPS for the current year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.26%. Johnson &amp; Johnson's dividend payout ratio (DPR) is 71.78%. </p><h2>Insider Transactions at Johnson &amp; Johnson</h2><p>In other news, VP Robert J. Decker sold 5,635 shares of the firm's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders. </p><h2>Johnson &amp; Johnson Company Profile</h2> (Free Report)<p>Johnson &amp; Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.</p><h2>Read More</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>Compound Interest and Why It Matters When Investing</li><li>Williams-Sonoma Stock: Buy It and Never Let It Go</li><li>3 Ways To Invest In Coffee, Other Than Drinking It</li><li>5 Dividend ETFs to Buy and Hold Forever</li><li>With Risk Tolerance, One Size Does Not Fit All</li><li>Berkshire Buys POOL Stock: Is It Time to Take the Plunge?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ [625,000% Gain] – Are You Ready for the Next Altcoin Boom? <span><span>(From Crypto Swap Profits)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE2Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE2Mg"/></p><h2>Should you invest $1,000 in Johnson &amp; Johnson right now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Altman Advisors Inc. has acquired a new position in Johnson & Johnson (NYSE:JNJ), purchasing 9,711 shares valued at approximately $574,000 during the 3rd quarter. Other institutional investors have also adjusted their stakes in the company. Analysts have raised price targets for JNJ, with a consensus rating of "Moderate Buy" and a price target of $94. Johnson & Johnson reported a quarterly EPS of $2.42, exceeding estimates, and announced a dividend of $1.24 per share, yielding 3.26%.</p>

Altman Advisors Inc. Makes New $1.57 Million Investment in Johnson & Johnson (NYSE:JNJ)